Detalles de la búsqueda
1.
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res;
26(1): 69, 2024 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38650031
2.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Lancet Oncol;
21(6): 821-831, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32437664
3.
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Oncologist;
25(4): 327-333, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297439
4.
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Breast Cancer Res;
26(1): 83, 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38790033
5.
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Cancer;
125(9): 1459-1469, 2019 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30620391
6.
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Cancer;
124(10): 2115-2124, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29517810
7.
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Clin Cancer Res;
29(18): 3633-3640, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37406106
8.
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
JCO Precis Oncol;
5: 93-102, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34994593
9.
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.
JCO Precis Oncol;
52021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34095713
10.
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.
Eur Urol Oncol;
3(5): 695-699, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31412004
11.
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
J Thorac Oncol;
15(10): 1611-1623, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32540409
12.
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Clin Cancer Res;
26(11): 2535-2545, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32086345
13.
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.
Nat Cancer;
1(4): 382-393, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32864625
14.
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Clin Cancer Res;
26(10): 2354-2361, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32102950
15.
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Cancer Discov;
10(2): 198-213, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31806627
16.
BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.
Cancers (Basel);
11(9)2019 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31533235
17.
Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer.
JCO Precis Oncol;
32019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32923867
18.
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.
Exp Hematol Oncol;
8: 24, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31632838
19.
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.
Clin Cancer Res;
25(10): 3046-3053, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30808777
20.
Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.
Transl Lung Cancer Res;
8(3): 258-267, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31367539